CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
The company is moving towards complex and more differentiated products
Theradaptive's regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
This is a shot in the arm for the vaccine manufacturers
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
Subscribe To Our Newsletter & Stay Updated
